{"id":42899,"date":"2019-07-25T10:59:01","date_gmt":"2019-07-25T08:59:01","guid":{"rendered":"https:\/\/newserver.fyb.de\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/"},"modified":"2019-07-25T10:59:01","modified_gmt":"2019-07-25T08:59:01","slug":"gimv-and-co-investors-sell-breath-therapeutics-to-zambon","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/","title":{"rendered":"Gimv and co-investors sell Breath Therapeutics to Zambon"},"content":{"rendered":"<p>Antwerp (BE) \/ Munich \u2014 <strong>Gimv, Sofin\u00adnova <\/strong>and <strong>Gilde Health\u00adcare<\/strong> sell their shares in the biophar\u00admaceu\u00adti\u00adcal company <strong>Breath Thera\u00adpeu\u00adtics<\/strong>. The company, which specia\u00adli\u00adzes in the deve\u00adlo\u00adp\u00adment of first-in-class inha\u00adla\u00adtion solu\u00adti\u00adons for severe lung dise\u00ada\u00adses, raised appro\u00adxi\u00adm\u00adately \u20ac43.5 million in 2017 in one of the largest Euro\u00adpean Series A rounds to date. With the support of the inves\u00adtors, two global Phase III studies on inha\u00adla\u00adtion therapy solu\u00adti\u00adons for the rare lung dise\u00adase Bron\u00adchio\u00adli\u00adtis Obli\u00adterans Syndrome (BOS) have now been initia\u00adted. There is curr\u00adently no appro\u00adved therapy for BOS and the dise\u00adase is fatal in many cases. The buyer of Breath Thera\u00adpeu\u00adtics is the Italian family-owned phar\u00admaceu\u00adti\u00adcal and chemi\u00adcal company Zambon.<\/p>\n<p>Gimv joined Sofin\u00adnova Part\u00adners (France) as lead inves\u00adtor in Breath Thera\u00adpeu\u00adtics in March 2017. Other inves\u00adtors were Gilde Health\u00adcare (Nether\u00adlands) and <strong>PARI Pharma<\/strong> as licen\u00adsor for the inha\u00adla\u00adtion devices. In addi\u00adtion to the finan\u00adcial support, Gimv\u2019s exper\u00adtise was also crucial to the success of the spin-out process, to the syndi\u00adca\u00adtion of the finan\u00adcing struc\u00adture, to the imple\u00admen\u00adta\u00adtion of the stra\u00adtegy, and to the imple\u00admen\u00adta\u00adtion of lean, inter\u00adnal proces\u00adses. Thanks to this exter\u00adnal know-how, Breath Thera\u00adpeu\u00adtics has been able to further deve\u00adlop its own inno\u00adva\u00adtion capa\u00adbi\u00adli\u00adties into a mature therapy solu\u00adtion, as well as to build up a top-class team of experts in Europe and the&nbsp;USA.<\/p>\n<p><strong>Dr. Karl N\u00e4gler,<\/strong>  Part\u00adner and respon\u00adsi\u00adble for the Health &amp; Care plat\u00adform at Gimv Germany, says: \u201cWe are even more plea\u00adsed with the successful deve\u00adlo\u00adp\u00adment of the company over the past two years, as Gimv was signi\u00adfi\u00adcantly invol\u00adved in the stra\u00adte\u00adgic direc\u00adtion and setting up of the plat\u00adform for growth from the very begin\u00adning. The poten\u00adtial of Breath Thera\u00adpeu\u00adtics and the compound was clear to us at an early stage, as lung dise\u00ada\u00adses are unfort\u00adu\u00adna\u00adtely on the rise \u2014 espe\u00adci\u00adally due to envi\u00adron\u00admen\u00adtal factors and chan\u00adging life\u00adstyles. Against this back\u00adground, with Zambon\u2019s support, Breath Thera\u00adpeu\u00adtics is in an excel\u00adlent posi\u00adtion to successfully commer\u00adcia\u00adlize the product in the future and to deve\u00adlop new fields of application.\u201d<\/p>\n<p>Dr. Jens Stege\u00admann, Chief Execu\u00adtive Offi\u00adcer at Breath Thera\u00adpeu\u00adtics, adds: \u201cWith this compound, Breath Thera\u00adpeu\u00adtics has deve\u00adlo\u00adped a product that can signi\u00adfi\u00adcantly improve the lives of many people. We have found a part\u00adner that shares our vision in Zambon, an inno\u00adva\u00adtive company with high ethi\u00adcal stan\u00addards and a clear focus on pati\u00adent well-being. Alre\u00adady, we have advan\u00adced the deve\u00adlo\u00adp\u00adment of a poten\u00adtial first-in-class therapy for BOS, initia\u00adted two global Phase III trials, and are thus excel\u00adlently posi\u00adtio\u00adned in the market. Thanks to Zambon\u2019s infra\u00adstruc\u00adture, exper\u00adtise and clear focus on rese\u00adarch and deve\u00adlo\u00adp\u00adment, we can acce\u00adle\u00adrate these proces\u00adses even further and make the treat\u00adment available to as many people as possi\u00adble as quickly as possi\u00adble. We would like to thank our former part\u00adners Gimv, Sofin\u00adnova and Gilde Health\u00adcare for their support, which was crucial to the successful deve\u00adlo\u00adp\u00adment of our company, espe\u00adci\u00adally in the early&nbsp;years.\u201d<\/p>\n<p>This tran\u00adsac\u00adtion increa\u00adses Gimv\u2019s NAV by EUR 20 million (as of March 31, 2019). With this invest\u00adment, Gimv achie\u00adved an ROI above its stated long-term target of&nbsp;15%.<\/p>\n<p><strong>About Gimv<\/strong><br>\nGimv is a Euro\u00adpean invest\u00adment company with almost 40 years of expe\u00adri\u00adence in private equity. The company is listed on Euron\u00adext Brussels, curr\u00adently mana\u00adges around EUR 1.1 billion and curr\u00adently invests in 55 port\u00adfo\u00adlio compa\u00adnies, which toge\u00adther realize a turno\u00adver of more than EUR 2.75 billion and employ 14,000 people.<\/p>\n<p>Gimv iden\u00adti\u00adfies inno\u00adva\u00adtive, leading compa\u00adnies with high growth poten\u00adtial and supports them on their way to market leader\u00adship. Each of the four invest\u00adment plat\u00adforms Connec\u00adted Consu\u00admer, Health &amp; Care, Smart Indus\u00adtries and Sustainable Cities is mana\u00adged by a dedi\u00adca\u00adted and compe\u00adtent team, each based in Gimv\u2019s home markets \u2014 Bene\u00adlux, France and DACH \u2014 and supported by an exten\u00adsive inter\u00adna\u00adtio\u00adnal network of experts.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antwerp (BE) \/ Munich \u2014 Gimv, Sofin\u00adnova and Gilde Health\u00adcare sell their shares in the biophar\u00admaceu\u00adti\u00adcal company Breath Thera\u00adpeu\u00adtics. The company, which specia\u00adli\u00adzes in the deve\u00adlo\u00adp\u00adment of first-in-class inha\u00adla\u00adtion solu\u00adti\u00adons for severe lung dise\u00ada\u00adses, raised appro\u00adxi\u00adm\u00adately \u20ac43.5 million in 2017 in one of the largest Euro\u00adpean Series A rounds to date. With the support of&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42912,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-42899","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-private-equity-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gimv and co-investors sell Breath Therapeutics to Zambon - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gimv and co-investors sell Breath Therapeutics to Zambon - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Antwerp (BE) \/ Munich \u2014 Gimv, Sofin\u00adnova and Gilde Health\u00adcare sell their shares in the biophar\u00admaceu\u00adti\u00adcal company Breath Thera\u00adpeu\u00adtics. The company, which specia\u00adli\u00adzes in the deve\u00adlo\u00adp\u00adment of first-in-class inha\u00adla\u00adtion solu\u00adti\u00adons for severe lung dise\u00ada\u00adses, raised appro\u00adxi\u00adm\u00adately \u20ac43.5 million in 2017 in one of the largest Euro\u00adpean Series A rounds to date. With the support of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-25T08:59:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Gimv and co-investors sell Breath Therapeutics to Zambon\",\"datePublished\":\"2019-07-25T08:59:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\"},\"wordCount\":619,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\",\"url\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\",\"name\":\"Gimv and co-investors sell Breath Therapeutics to Zambon - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg\",\"datePublished\":\"2019-07-25T08:59:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg\",\"width\":512,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gimv and co-investors sell Breath Therapeutics to Zambon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gimv and co-investors sell Breath Therapeutics to Zambon - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/","og_locale":"en_US","og_type":"article","og_title":"Gimv and co-investors sell Breath Therapeutics to Zambon - FYB Financial Yearbook","og_description":"Antwerp (BE) \/ Munich \u2014 Gimv, Sofin\u00adnova and Gilde Health\u00adcare sell their shares in the biophar\u00admaceu\u00adti\u00adcal company Breath Thera\u00adpeu\u00adtics. The company, which specia\u00adli\u00adzes in the deve\u00adlo\u00adp\u00adment of first-in-class inha\u00adla\u00adtion solu\u00adti\u00adons for severe lung dise\u00ada\u00adses, raised appro\u00adxi\u00adm\u00adately \u20ac43.5 million in 2017 in one of the largest Euro\u00adpean Series A rounds to date. With the support of [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2019-07-25T08:59:01+00:00","og_image":[{"width":512,"height":512,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Gimv and co-investors sell Breath Therapeutics to Zambon","datePublished":"2019-07-25T08:59:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/"},"wordCount":619,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/","url":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/","name":"Gimv and co-investors sell Breath Therapeutics to Zambon - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg","datePublished":"2019-07-25T08:59:01+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/07\/a-gilde.jpg","width":512,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/gimv-and-co-investors-sell-breath-therapeutics-to-zambon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Gimv and co-investors sell Breath Therapeutics to Zambon"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42899"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42899\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42912"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}